ArticleViruses2025
A Feasibility Study of a Rapid Lateral Flow Immunoassay Test for Children and Adolescents to Determine SARS-CoV-2 Seroprevalence.
Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global seroprevalence of SARS-CoV-2 in children and adolescents has risen to an estimated 56.6%. Limited data on children highlights the need for ongoing surveillance as recommended by the WHO. Understanding this need, in this study we carry out a feasibility study of a rapid lateral flow immunoassay test (LFIAT) and determine SARS-CoV-2 seroprevalence in children and adolescents. The method used in the paper included 202 children (1-18 years old) who were evaluated for SARS-CoV-2 IgG/IgM antibodies using the LFIAT. LFIAT provides results in 20 min. Demographic data was collected through questionnaires. As a result, SARS-CoV-2 antibody seroprevalence was 52.0% (n = 105). No gender differences were observed. Adolescents exhibited higher seroprevalence (63.0%) compared to children aged 1-5.9 (49.3%) and 6-11.9 years old (46.8%), without statistical significance (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.